[ad_1] Japan’s health agency has approved AstraZeneca Plc’s AZN Koselugo (selumetinib) for pediatric patients with plexiform neurofibromas (PNs) in neurofibromatosis type 1 (NF1) with clinical symptoms and which cannot be entirely removed…
[ad_1] Gain Therapeutics Inc GANX announced the presentation of new preclinical data evaluating one of its lead Structurally Targeted Allosteric Regulator (STAR) compounds, GT-02287, for Parkinson’s Disease. The study was conducted…
[ad_1] SIGA Technologies Inc SIGA received approximately $16 million in international procurement orders for oral TPOXX (tecovirimat) in August and early September. The orders include an approximate $10 million order by…
[ad_1] Switzerland would have to discard 10.3 million doses of Moderna Inc’s MRNA COVID-19 vaccine, the health ministry said Saturday. The ministry said it had no choice but to eliminate the shots…
[ad_1] Yesterday, the FDA’s Oncologic Drugs Advisory Committee (ODAC) panel voted against Spectrum Pharmaceuticals Inc’s SPPI poziotinib’s (pozi) risk/benefit ratio and concluded that pozi’s benefits do not outweigh the risks for the…
[ad_1] Avenue Therapeutics Inc ATXI received the official meeting minutes from the FDA regarding a meeting conducted for IV Tramadol in combination with other opioid analgesics to manage moderate-to-moderately severe pain. …
[ad_1] Citius Pharmaceuticals Inc CTXR collaborated with the University of Pittsburgh for I/ONTAK (denileukin diftitox or E7777) in combination with Merck & Company, Inc. MRK Keytruda (pembrolizumab) for recurrent or metastatic solid tumors. …
[ad_1] Luna Innovations Inc LUNA announced a new $14.2 million contract with its long-standing partner Intuitive Surgical Inc ISRG. This new agreement provides for the supply of critical photonic subsystems manufactured by Luna…
[ad_1] Inventiva IVA and Chia Tai-Tianqing Pharmaceutical Group Co Ltd, a Sino Biopharm subsidiary, have entered into a licensing and collaboration agreement to develop and commercialize lanifibranor for non-alcoholic steatohepatitis (NASH) and potentially other metabolic…
[ad_1] On Tuesday, the FDA released briefing documents related to Spectrum Pharmaceutical Inc’s SPPI application for poziotinib for treating patients with previously treated locally advanced or metastatic NSCLC. HC Wainwright says that though…
[ad_1] The FDA warned that certain types of Medtronic Inc’s MDT MiniMed 600 Series insulin pump system were vulnerable to cyberattacks. Hackers could potentially hamper insulin delivery by accessing the device. …
[ad_1] Pacira BioSciences Inc PCRX announced topline results from its Phase 3 study of EXPAREL as a single-dose sciatic nerve block in the popliteal fossa for postsurgical regional analgesia in patients undergoing…
[ad_1] Ahead of an adcomm meeting for Spectrum Pharmaceutical Inc SPPI, FDA released briefing documents related to poziotinib for treating patients with previously treated locally advanced or metastatic NSCLC harboring HER2…
[ad_1] England’s National Institute for Health and Care Excellence (NICE) has recommended BeiGene Ltd’s BGNE Brukinsa (zanubrutinib) for Waldenström’s Macroglobulinemia (WM) in adults who have had at least one treatment, only if…
[ad_1] A U.S. judge on Monday denied the Justice Department’s request to stop UnitedHealth Group Inc’s UNH $13 billion buyout deal for Change Healthcare Inc CHNG. The Justice Department had filed a…
[ad_1] Virios Therapeutics Inc’s VIRI shares crashed after its FORTRESS Phase 2b trial of IMC-1 antiviral combination therapy for fibromyalgia failed to meet the primary endpoint. Fibromyalgia is a disorder…
[ad_1] Trevi Therapeutics Inc TRVI announced results from the full set of subjects in its Phase 2 CANAL trial of Haduvio for treating chronic cough in idiopathic pulmonary fibrosis (IPF). Following…
[ad_1] AstraZeneca Plc AZN said its Danicopan add-on anti-blood-clotting drug met a primary endpoint in the ALPHA phase 3 trial in patients with paroxysmal nocturnal hemoglobinuria (PNH) who experience clinically significant extravascular…
[ad_1] Pfizer Inc PFE has dosed the first participants in the Phase 3 trial of its quadrivalent modified RNA (modRNA) influenza vaccine candidate in approximately 25,000 healthy U.S. adults. Influenza annually…
[ad_1] Atea Pharmaceuticals Inc AVIR announced additional details on its clinical development plans for bemnifosbuvir for COVID-19. Following meetings with the FDA and the European Medicines Agency Emergency Task Force, Atea…
[ad_1] AbbVie Inc ABBV announced new, long-term data analyses of KEEPsAKE 1 and 2, Phase 3 trials of Skyrizi (risankizumab) in active psoriatic arthritis. Results showed that at week 100 of…
[ad_1] Bloomberg Tesla, Nio Supplier CATL’s Chinese Rival Eyes $2B Hong Kong IPO Chinese battery maker CALB Co., a rival to companies like Contemporary Amperex Technology Co Ltd. (CATL)…
[ad_1] The FDA approved Bristol Myers Squibb Co’s BMY Sotyktu (deucravacitinib), an allosteric tyrosine kinase 2 (TYK2) inhibitor, for moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Sotyktu…
[ad_1] Regeneron Pharmaceuticals Inc REGN announced early data for ubamatamab in recurrent ovarian cancer and REGN5093 in MET-altered advanced non-small cell lung cancer (NSCLC). Within 42 patients who received full doses…
[ad_1] Bloomberg When The Bank Error Is Not In Your Favor: Pay Back $500 Million Citigroup Inc C has won an appeal to retrieve $500 million that was sent…